Limits...
Eag1 channels as potential early-stage biomarkers of hepatocellular carcinoma

View Article: PubMed Central - PubMed

ABSTRACT

Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide. HCC is usually asymptomatic at potential curative stages, and it has very poor prognosis if detected later. Thus, the identification of early biomarkers and novel therapies is essential to improve HCC patient survival. Ion channels have been proposed as potential tumor markers and therapeutic targets for several cancers including HCC. Especially, the ether à-go-go-1 (Eag1) voltage-gated potassium channel has been suggested as an early marker for HCC. Eag1 is overexpressed during HCC development from the cirrhotic and the preneoplastic lesions preceding HCC in a rat model. The channel is also overexpressed in human HCC. Astemizole has gained great interest as a potential anticancer drug because it targets several proteins involved in cancer including Eag1. Actually, in vivo studies have shown that astemizole may have clinical utility for HCC prevention and treatment. Here, we will review first some general aspects of HCC including the current biomarkers and therapies, and then we will focus on Eag1 channels as promising tools in the early diagnosis of HCC.

No MeSH data available.


Related in: MedlinePlus

Follow-up for patients at risk of HCC.Notes: The early screening should help to detect HCC when treatable. This screening should be performed, especially in patients with liver diseases at risk of developing HCC, and Eag1 detection may be also included in this screening.Abbreviations: AFP, alfa-fetoprotein; CT, computed tomography; Eag1, ether à-go-go-1; HCC, hepatocellular carcinoma; MRI, magnetic resonance imaging; US, ultrasound.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC5036561&req=5

f2-btt-10-139: Follow-up for patients at risk of HCC.Notes: The early screening should help to detect HCC when treatable. This screening should be performed, especially in patients with liver diseases at risk of developing HCC, and Eag1 detection may be also included in this screening.Abbreviations: AFP, alfa-fetoprotein; CT, computed tomography; Eag1, ether à-go-go-1; HCC, hepatocellular carcinoma; MRI, magnetic resonance imaging; US, ultrasound.

Mentions: Because most HCC cases are associated with chronic viral hepatitis, prevention of virus infection should lead to the prevention of HCC.11–13 Some preventive strategies already used include vaccination (the universal vaccination was introduced in all newborns and high-risk groups as routine immunization13–15), antiviral treatment (it has been shown that antiviral treatment of chronic hepatitis B virus and hepatitis C virus infections may reduce the risk of HCC13,16,17), and periodical surveillance in patients at risk of developing a disease (Figure 2).11,13,18


Eag1 channels as potential early-stage biomarkers of hepatocellular carcinoma
Follow-up for patients at risk of HCC.Notes: The early screening should help to detect HCC when treatable. This screening should be performed, especially in patients with liver diseases at risk of developing HCC, and Eag1 detection may be also included in this screening.Abbreviations: AFP, alfa-fetoprotein; CT, computed tomography; Eag1, ether à-go-go-1; HCC, hepatocellular carcinoma; MRI, magnetic resonance imaging; US, ultrasound.
© Copyright Policy
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC5036561&req=5

f2-btt-10-139: Follow-up for patients at risk of HCC.Notes: The early screening should help to detect HCC when treatable. This screening should be performed, especially in patients with liver diseases at risk of developing HCC, and Eag1 detection may be also included in this screening.Abbreviations: AFP, alfa-fetoprotein; CT, computed tomography; Eag1, ether à-go-go-1; HCC, hepatocellular carcinoma; MRI, magnetic resonance imaging; US, ultrasound.
Mentions: Because most HCC cases are associated with chronic viral hepatitis, prevention of virus infection should lead to the prevention of HCC.11–13 Some preventive strategies already used include vaccination (the universal vaccination was introduced in all newborns and high-risk groups as routine immunization13–15), antiviral treatment (it has been shown that antiviral treatment of chronic hepatitis B virus and hepatitis C virus infections may reduce the risk of HCC13,16,17), and periodical surveillance in patients at risk of developing a disease (Figure 2).11,13,18

View Article: PubMed Central - PubMed

ABSTRACT

Hepatocellular carcinoma (HCC) is a major cause of cancer death worldwide. HCC is usually asymptomatic at potential curative stages, and it has very poor prognosis if detected later. Thus, the identification of early biomarkers and novel therapies is essential to improve HCC patient survival. Ion channels have been proposed as potential tumor markers and therapeutic targets for several cancers including HCC. Especially, the ether à-go-go-1 (Eag1) voltage-gated potassium channel has been suggested as an early marker for HCC. Eag1 is overexpressed during HCC development from the cirrhotic and the preneoplastic lesions preceding HCC in a rat model. The channel is also overexpressed in human HCC. Astemizole has gained great interest as a potential anticancer drug because it targets several proteins involved in cancer including Eag1. Actually, in vivo studies have shown that astemizole may have clinical utility for HCC prevention and treatment. Here, we will review first some general aspects of HCC including the current biomarkers and therapies, and then we will focus on Eag1 channels as promising tools in the early diagnosis of HCC.

No MeSH data available.


Related in: MedlinePlus